Table 3. Relationship between changes in clinical laboratory r and hepatitis C viral genotypes (n = 280).
| Index | HCV-1 | HCV-2 | HCV-3 | HCV-6 | p (ANOVA) | r2 |
|---|---|---|---|---|---|---|
| ΔALP (IU/L, mean ± SD) | -77.5±232 | -39.7±75.9 | 28.4±25.5 | -108.8±326.6 | 0.303 | 0.004 |
| ΔAST (IU/L, mean ± SD) | -70.7±285.4 | -25±55.2 | -16.9±14.5 | -59.5±249 | 0.803 | 0.001 |
| ΔBILT (mg/dL, mean ± SD) | -41.6±87 | -54.5±97.9 | -65.7±96.8 | -38.2±81 | 0.662 | 0.001 |
| ΔUric acid (μmol/L, mean ± SD) | 43±181.8 | 38.1±173.5 | 40.6±101.1 | 46.8±173.8 | 0.847 | 0.001 |
| ΔChol (mmol/L, mean ± SD) | 1.2±3.3 | 2±5.8 | -0.3±1.8 | 0.8±3.2 | 0.283 | 0.005 |
| ΔHDL cholesterol (mmol/L, mean ± SD) | 0.5±1.3 | 0.4±0.4 | 1.1±2.2 | 0.5±1.1 | 0.416 | 0.011 |
| ΔLDL cholesterol (mmol/L, mean ± SD) | -2.1±3.5 | -1.2±3.3 | -4±3.6 | -2.5±3.6 | 0.244 | 0.015 |
| ΔGlucose (mmol/L, mean ± SD) | -2±7.2 | -3.6±7.3 | -0.1±2.1 | -1.4±4.9 | 0.302 | 0.004 |
| ΔHbA1C (%, mean ± SD) | -2.6±2.9 | -0.8±3.9 | -2±3.6 | -1.6±2.8 | 0.041 | 0.01 |
| ΔHGB (g/L, mean ± SD) | -8±21.2 | -0.5±23.9 | -15.9±20 | -1.5±21.9 | 0.031 | 0.032 |
| ΔHCT (%, mean ± SD) | -0.11±0.11 | -0.04±0.12 | -0.08±0.13 | -0.07±0.11 | 0.041 | 0.03 |
| ΔPLT (g/L, mean ± SD) | -14.6±88.2 | -32±69.7 | -22.3±131.9 | -9.3±70.4 | 0.754 | 0.005 |
| ΔCRE (g/L, mean ± SD) | 4.4±22.3 | 8.9±14.2 | 4.7±25.9 | 14.6±116.4 | 0.315 | 0.004 |
| ΔGFR (mL/min, mean ± SD) | -8.6±34.4 | -10.9±20.1 | -11.6±44.6 | -17±44.1 | 0.344 | 0.011 |
∆ = level after 12 weeks of treatment–level at baseline; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HbA1C: Hemoglobin A1C; GFR: Glomerular filtration rate; PLT: Platelet count; CRE: Creatinine; HCT: Hematocrit; BILT: Total bilirubin; Chol: Total cholesterol.